{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Filgrastim+or+equivalent", "query": { "intervention": "Filgrastim or equivalent" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 46, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Filgrastim+or+equivalent&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T03:57:25.774Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01164475", "title": "Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Granulocyte-colony stimulating factor (G-CSF)", "type": "DRUG" }, { "name": "Fixed Dose Plerixafor", "type": "DRUG" }, { "name": "Weight-Based Plerixafor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "78 Years", "sex": "ALL", "summary": "18 Years to 78 Years" }, "enrollment_count": 61, "start_date": "2010-10", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-02-25", "last_synced_at": "2026-09-13T03:57:25.774Z", "location_count": 2, "location_summary": "Duarte, California • Aurora, Colorado", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01164475" }, { "nct_id": "NCT04959175", "title": "Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Allogeneic HSCT", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "12 Years to 85 Years" }, "enrollment_count": 320, "start_date": "2021-09-23", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-09-13T03:57:25.774Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04959175" }, { "nct_id": "NCT00092222", "title": "Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoproliferative Disorder", "HHV-8", "Malignancy", "HIV" ], "interventions": [ { "name": "Etoposide", "type": "DRUG" }, { "name": "Interferon-alpha", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Liposomal Doxorubicin", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim (G-CSF)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Observation Only", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2004-10-28", "completion_date": "2026-10-01", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-13T03:57:25.774Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00092222" }, { "nct_id": "NCT00048893", "title": "Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Neoplasms", "Metastases, Neoplasm" ], "interventions": [ { "name": "recombinant fowlpox-CEA(6D)/TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant vaccinia-CEA(6D)/TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2002-11", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2012-04-13", "last_synced_at": "2026-09-13T03:57:25.774Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Hackensack, New Jersey", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00048893" }, { "nct_id": "NCT00066482", "title": "Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "MESNA", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 19, "start_date": "2004-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-10-17", "last_synced_at": "2026-09-13T03:57:25.774Z", "location_count": 88, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066482" }, { "nct_id": "NCT00520130", "title": "Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome", "Hodgkin's Lymphoma", "Non-Hodgkin's Disease", "Acute Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Allogenic stem cell transplant (ASCT)", "type": "DRUG" }, { "name": "Conditioning Chemotherapy", "type": "DRUG" }, { "name": "TMS", "type": "DRUG" }, { "name": "FLAG", "type": "DRUG" }, { "name": "EPOCH-F", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 92, "start_date": "2007-10-30", "completion_date": "2018-12-31", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-09-13T03:57:25.774Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00520130" }, { "nct_id": "NCT00245037", "title": "Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Precancerous Condition" ], "interventions": [ { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "Total Body Irradiation (TBI)", "type": "RADIATION" }, { "name": "Granulocyte colony-stimulating factor (G-CSF)", "type": "DRUG" }, { "name": "Phenytoin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 147, "start_date": "2005-06", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-09-27", "last_synced_at": "2026-09-13T03:57:25.774Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00245037" }, { "nct_id": "NCT02793544", "title": "HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome (MDS)", "Chronic Lymphocytic Leukemia (CLL)", "Chemotherapy-sensitive Lymphoma", "Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma", "Acute Myelogenous Leukemia (AML)", "Acute Biphenotypic Leukemia (ABL)", "Acute Undifferentiated Leukemia (AUL)" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI) 200cGy on Day -1", "type": "RADIATION" }, { "name": "Infusion of non-T-cell depleted bone marrow on Day 0", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide 50mg/kg/day IV on Days -2,-1", "type": "DRUG" }, { "name": "Cyclophosphamide 50mg/kg/day IV on Days -5,-4", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1", "type": "RADIATION" }, { "name": "Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -6 and -5", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -2 and -1", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -5 and -4", "type": "DRUG" }, { "name": "Post-HCT Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "15 Years to 70 Years" }, "enrollment_count": 80, "start_date": "2016-12", "completion_date": "2020-03", "has_results": true, "last_update_posted_date": "2025-08-06", "last_synced_at": "2026-09-13T03:57:25.774Z", "location_count": 11, "location_summary": "Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02793544" }, { "nct_id": "NCT00446030", "title": "Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 127, "start_date": "2007-03", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2012-06-26", "last_synced_at": "2026-09-13T03:57:25.774Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00446030" }, { "nct_id": "NCT06312137", "title": "A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Rescue medication", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 780, "start_date": "2024-04-03", "completion_date": "2034-10-23", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-13T03:57:25.774Z", "location_count": 50, "location_summary": "Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 40 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06312137" } ] }